Farxiga (Dapagliflozin) Cost in Illinois: 2026 Pricing, Insurance, and Savings Guide

What Farxiga Costs in Illinois Right Now

The average cash price for a 30-day supply of Farxiga 10 mg at Illinois retail pharmacies sits at roughly $620 in 2026, matching AstraZeneca's national list price. That figure applies to uninsured patients paying out of pocket at chains like Walgreens, CVS, or Jewel-Osco. Prices can fluctuate by $30 to $50 between pharmacies in the same metro area, so calling ahead or checking GoodRx-type platforms before filling is worth the two minutes it takes.

For context, dapagliflozin belongs to the SGLT2 inhibitor class. The FDA approved Farxiga for type 2 diabetes in 2014, then expanded the label to include heart failure with reduced ejection fraction in 2020 and chronic kidney disease (CKD) in 2021 [1]. Each new indication widened the pool of patients who might need to manage Illinois pricing. No FDA-approved generic version of dapagliflozin exists as of May 2026, which keeps list prices elevated compared to older diabetes drugs like metformin, where generics run $4 to $15 per month [2].

Illinois ranks among the top ten states in SGLT2 inhibitor prescriptions per capita, driven partly by high rates of type 2 diabetes. The CDC estimates that 11.7% of Illinois adults have diagnosed diabetes [3]. That translates to over 1.1 million residents, many of whom could benefit from dapagliflozin's cardiorenal protections but face real cost barriers at $620 per month without coverage.

Illinois Medicaid Coverage for Farxiga

Illinois Medicaid does cover Farxiga, but it requires prior authorization. The Illinois Department of Healthcare and Family Services (HFS) lists dapagliflozin on the preferred drug list for type 2 diabetes management when metformin alone provides inadequate glycemic control. Approval typically requires documentation that the patient has tried metformin (or has a contraindication) and has an HbA1c at or above 7% as measured within the preceding 90 days [4].

For heart failure and CKD indications, the PA pathway differs. Prescribers must submit clinical notes showing a left ventricular ejection fraction of 40% or less (for the HF indication) or an eGFR between 25 and 75 mL/min/1.73 m² (for CKD). The DAPA-CKD trial (N=4,304) demonstrated that dapagliflozin reduced the composite of sustained eGFR decline, end-stage kidney disease, or renal death by 44% versus placebo (HR 0.56, 95% CI 0.45 to 0.68, P<0.001) [5]. Illinois Medicaid reviewers weigh this evidence when adjudicating PA requests for CKD patients.

Processing time runs 3 to 5 business days for standard requests. Urgent or expedited PAs can be completed within 24 hours when the prescriber indicates clinical urgency. Denials can be appealed through the HFS fair hearing process. If you are on a Medicaid managed care plan (such as Meridian, Molina, or Blue Cross Community), PA criteria may vary slightly from fee-for-service Medicaid, so confirm with your specific MCO.

Commercial Insurance and Farxiga in Illinois

Most major commercial plans operating in Illinois, including Blue Cross Blue Shield of Illinois, Aetna, Cigna, and UnitedHealthcare, cover Farxiga on their formularies. It typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), producing copays that range from $25 to $75 per month after the deductible is met.

Prior authorization is standard across nearly all commercial payers. The documentation requirements mirror Medicaid: evidence of metformin failure or intolerance for the diabetes indication, or appropriate cardiac or renal markers for HF/CKD. Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has noted that "SGLT2 inhibitors have moved from second-line add-ons to first-line considerations in patients with established cardiovascular disease or CKD, regardless of glycemic status" [6]. This shift in clinical positioning has pushed more insurers to cover dapagliflozin, though the PA requirement persists.

High-deductible health plans (HDHPs) present a different challenge. Until the annual deductible ($1,600 to $3,200 for individuals in 2026) is met, patients bear the full $620 monthly cost. The AstraZeneca savings card (discussed below) can offset much of this burden for commercially insured patients, but it does not apply to government-funded plans like Medicare Part D or Medicaid.

The DAPA-HF trial (N=4,744) showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74, 95% CI 0.65 to 0.85, P<0.001), with a number needed to treat of 21 over a median 18.2-month follow-up [7]. This data strengthens PA approvals for the heart failure indication and has made coverage denials less frequent since the label expansion.

The AstraZeneca Savings Card: How It Works in Illinois

AstraZeneca offers a manufacturer copay savings card for Farxiga that can reduce out-of-pocket costs to as low as $0 per month for eligible patients. The card covers up to $200 per 30-day fill for commercially insured patients.

Eligibility rules are straightforward. You must have commercial (private) insurance. You cannot use the card if you are enrolled in Medicare, Medicaid, TRICARE, or any other federal or state healthcare program. Illinois residents with employer-sponsored or marketplace (ACA) insurance qualify. The card is valid for up to 24 months and can be re-enrolled annually.

To activate the card, patients visit the Farxiga website, complete a brief eligibility form, and receive a digital or physical card. Present it at the pharmacy along with your insurance card. The pharmacist processes insurance first, then applies the savings card to cover remaining copay or coinsurance amounts up to the monthly cap.

One limitation: the $200 monthly cap may not fully cover the gap for patients on HDHPs who have not yet met their deductible. If insurance has not applied any coverage, the patient faces $620 minus $200, leaving $420 out of pocket. Once the deductible is met and the plan pays its share, the savings card typically reduces the remaining copay to $0.

Compounded Dapagliflozin in Illinois

Compounded dapagliflozin is available through licensed 503A compounding pharmacies operating in Illinois. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions [8]. Illinois law aligns with federal 503A provisions, allowing compounding pharmacies to prepare dapagliflozin formulations when a prescriber writes a patient-specific prescription.

This pathway exists because Farxiga is not on the FDA's "demonstrably difficult to compound" list, and dapagliflozin is commercially available as a finished product. Some compounding pharmacies offer dapagliflozin at significantly reduced prices compared to the branded product. Pricing varies by pharmacy, but patients should verify that the compounding pharmacy holds a valid Illinois Board of Pharmacy license and operates under 503A regulations.

A few clinical considerations matter here. Compounded medications are not FDA-approved products. They do not undergo the same bioequivalence testing as generic drugs. The 2023 ADA Standards of Care state that "clinicians should ensure patients receive medications from regulated sources with appropriate quality controls" [4]. Patients choosing compounded dapagliflozin should discuss this option with their prescriber and confirm the pharmacy's accreditation status.

Farxiga via Telehealth in Illinois

Illinois permits telehealth prescribing of Farxiga without an in-person visit. The Illinois Telehealth Act, updated in 2021, allows physicians and advanced practice providers to prescribe non-controlled medications through audio-video consultations. Since dapagliflozin is not a controlled substance, it qualifies.

Telehealth platforms that operate in Illinois can evaluate patients, order labs, and write Farxiga prescriptions that are filled at any Illinois retail or mail-order pharmacy. This is particularly useful for patients in rural downstate counties where endocrinology or cardiology specialists may be scarce. Roughly 35 of Illinois' 102 counties are classified as medically underserved by the Health Resources and Services Administration [9].

Lab monitoring is part of ongoing dapagliflozin therapy. Prescribers typically check serum creatinine, eGFR, potassium, and HbA1c before starting the drug and periodically thereafter. Telehealth providers can order these labs at local draw stations (Quest, Labcorp, or hospital outpatient labs), review results remotely, and adjust therapy without requiring the patient to drive hours for a face-to-face visit.

The 2022 ADA/KDIGO consensus report recommends initiating an SGLT2 inhibitor in patients with type 2 diabetes and an eGFR of 20 mL/min/1.73 m² or higher, regardless of HbA1c level, when albuminuria is present [10]. Telehealth providers following these guidelines can identify and start appropriate candidates on dapagliflozin earlier in the disease course.

How to Lower Your Farxiga Cost in Illinois

Several strategies exist for reducing what you pay. The best approach depends on your insurance status.

Commercially insured patients: Apply for the AstraZeneca savings card first. If your plan covers Farxiga at Tier 3 or better, the savings card will likely bring your copay to $0. If your plan does not cover Farxiga, ask your prescriber to submit a PA with supporting clinical documentation. Include relevant trial data in the appeal. For example, the DECLARE-TIMI 58 trial (N=17,160) found dapagliflozin reduced hospitalization for heart failure by 27% (HR 0.73, 95% CI 0.61 to 0.88) [11].

Uninsured patients: AstraZeneca operates a patient assistance program (AZ&Me) for patients with household income at or below 400% of the federal poverty level. For a single individual in 2026, that threshold is approximately $62,400. Approved patients receive Farxiga at no cost. Application requires income verification and a prescriber signature.

Medicare Part D enrollees: The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drug spending took effect in 2025 [12]. Once you reach $2,000 in total out-of-pocket Part D costs for the year, you pay nothing more. Farxiga at $620/month would hit that cap within roughly 4 months, depending on your plan's cost-sharing structure. After that, the remaining 8 months of the year are $0.

Medicaid patients: Your copay is $0 to $4 per fill once the PA is approved. Medicaid covers the rest.

Mail-order pharmacies: Some Illinois patients save 10% to 15% by filling 90-day supplies through mail-order pharmacies like Express Scripts, OptumRx, or Costco mail order. Ask your insurer whether a 90-day fill reduces your per-unit cost.

Clinical Value: Why Dapagliflozin Justifies the Investment

Cost conversations should include clinical context. Dapagliflozin is not just a glucose-lowering drug. Its cardiorenal benefits extend to patients with heart failure and CKD independent of diabetes status. Dr. John McMurray, lead investigator of the DAPA-HF trial and professor of cardiology at the University of Glasgow, stated: "The benefits of dapagliflozin were consistent regardless of the presence or absence of diabetes, suggesting a mechanism beyond glucose lowering" [7].

The DAPA-CKD trial showed a 31% reduction in all-cause mortality (HR 0.69, 95% CI 0.53 to 0.88, P=0.004), a finding that led the trial's data safety monitoring board to recommend early termination due to overwhelming efficacy [5]. For patients with stage 3 or 4 CKD, the cost of Farxiga may be offset by avoided hospitalizations, delayed dialysis initiation, and preserved kidney function over years.

A 2023 cost-effectiveness analysis published in the Journal of the American Heart Association found that dapagliflozin for heart failure met conventional willingness-to-pay thresholds at $50,000 per quality-adjusted life year (QALY), with an incremental cost-effectiveness ratio of $47,800 per QALY gained [13]. In practical terms, the clinical return on each dollar spent on Farxiga compares favorably to many accepted cardiovascular interventions.

Comparing SGLT2 Inhibitor Costs in Illinois

Farxiga is not the only SGLT2 inhibitor on the market. Jardiance (empagliflozin, Boehringer Ingelheim/Lilly) carries a similar list price of approximately $610 to $630 per month. Invokana (canagliflozin, Janssen) is priced slightly lower at $570 to $590 per month but carries a boxed warning for lower-limb amputation risk that dapagliflozin and empagliflozin do not share [14].

For Illinois patients whose insurance covers one SGLT2 inhibitor but not another, therapeutic substitution is often possible. The 2024 ADA Standards of Care treat SGLT2 inhibitors as a class recommendation, noting that "cardiovascular and kidney benefits are likely a class effect, though individual trial data vary in population and outcomes measured" [15]. If your insurer covers Jardiance at Tier 2 but Farxiga at Tier 4, switching to empagliflozin may be clinically appropriate and financially advantageous, provided your prescriber agrees.

Generic empagliflozin is not yet available either. Both branded SGLT2 inhibitors remain under patent protection through at least 2027 to 2028, though exact expiration dates depend on ongoing patent litigation.